USA - engelska - NLM (National Library of Medicine)

dispensing solutions, inc. - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 1000 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia,

USA - engelska - NLM (National Library of Medicine)

redmont pharmaceuticals, llc - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - i. therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia (types iia and iib)† , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the ncep treatment guidelines6 ). prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, hdl cholesterol, and triglycerides. ii. nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (types iv and v hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. such patients typically have serum triglyceride levels over 2,000 mg/dl and have elevations of vldl cholesterol as well as fasting chylomicrons (type v hyperlipidemia)† . subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dl are unlikely to develop pancreatitis. therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dl who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. some type iv patients with triglycerides under 1,000 mg/dl may, through dietary or alcoholic indiscretion, convert to a type v pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. drug therapy is not indicated for patients with type i hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of vldl. inspection of plasma refrigerated for 14 hours is helpful in distinguishing types i, iv, and v hyperlipoproteinemia7 . nicotinic acid is contraindicated in patients with a known hypersensitivity to any component of this medication; significant or unexplained hepatic dysfunction; active peptic ulcer disease; or arterial bleeding.

USA - engelska - NLM (National Library of Medicine)

emerald therapeutics, llc - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - i. therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia (types iia and iib)† , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the ncep treatment guidelines6 ). prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, hdl cholesterol, and triglycerides. ii. nicotinic acid is

USA - engelska - NLM (National Library of Medicine)

redmont pharmaceuticals, llc - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - i. therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia (types iia and iib)†, when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the ncep treatment guidelines6 ). prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, hdl cholesterol, and triglycerides. ii. nicotinic acid is

USA - engelska - NLM (National Library of Medicine)

upsher-smith laboratories, llc - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 500 mg - i. therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and ldl cholesterol levels in patients with primary hypercholesterolemia (types iia and iib)† , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the ncep treatment guidelines6 ). prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, hdl cholesterol, and triglycerides. ii. nicotinic acid is

USA - engelska - NLM (National Library of Medicine)

mu-biz.co,.ltd - niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - niacinamide 0.40 g in 20 ml - purpose: skin brightening & anti wrinkle use: wrinkle care- the most effective anti-aging and wrinkle decreasing ingredient adenosine is contained in high concentration for wrinkle care. brighten- the niacinamide helps prevent uneven darkening and roughened skin.

USA - engelska - NLM (National Library of Medicine)

carilion materials management - niacin (unii: 2679mf687a) (niacin - unii:2679mf687a) - niacin 500 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. - niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. - niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. - in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. - in patients with a history of coronary artery disease (cad) and hyperlipidemia,

USA - engelska - NLM (National Library of Medicine)

nature republic co., ltd. - niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4) - niacinamide 0.40 g in 20 g - purpose: [brightening & skin moisturizing] this highly moisturizing hydrogel mask makes skin look healthy by providing energy to stressed-out skin. an active ingredient of niacinamide brightens the skin tone. how to use: 1. after applying toner, pull out mask sheet from package and unfold. 2. apply the mask sheet onto the face from the lower (chin) part of the mask and move upward towords the forehead. 3. remove mask sheet after 30 minutes. gently pat any remaining formula into skin. *use 2-3 times a week for the best result. *do not reuse mask sheets. how to use: 1. after applying toner, pull out mask sheet from package and unfold. 2. apply the mask sheet onto the face from the lower (chin) part of the mask and move upward towords the forehead. 3. remove mask sheet after 30 minutes. gently pat any remaining formula into skin. *use 2-3 times a week for the best result. *do not reuse mask sheets.

USA - engelska - NLM (National Library of Medicine)

j2d international - niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - niacinamide 1.0 g in 50 ml - purpose: skin brightening & anti wrinkle uses: moisturizing cream that improving skin texture by seahorse extract and re-dermax, and improving skin tone and wrinkle by niacinamide and adenosine.

USA - engelska - NLM (National Library of Medicine)

first cosmetic co., ltd - niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - niacinamide 0.54 g in 27 ml - purpose: skin brightening & anti wrinkle uses: the sparkling tablets containing natural fruit ingredients, vitamin c, b2 and b7 and the double functional cosmetic ample containing adenosine and niacinamide for wrinkle and whitening. the natural refreshing fruit ingredients and vitamin, aloe vera leaf, portulaca, rosemary and morus bark offer gentle and relaxing texture and let your skin breathe. when you put the tablet into the ample, it creates vitamin and sparkling bubbles. the bubbles enhance the functions of the ample containing hyaluronic acid, peptide and other herb extracts and help your skin get better moist and elastic.